首页> 外文期刊>Journal of Medicinal Chemistry >ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity
【24h】

ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity

机译:ICI 56,780优化:具有抗疟疾活性的7-(2-苯氧基乙氧基)-4(1H)-喹诺酮的结构-活性关系研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Though malaria mortality rates are down 48% globally since 2000, reported occurrences of resistance against current therapeutics threaten to reverse that progress. Recently, antimalarials that were once considered unsuitable therapeutic agents have been revisited to improve physicochemical properties and efficacy required for selection as a drug candidate. One such compound is 4(1H)-quinolone ICI 56,780, which is known to be a causal prophylactic that also displays blood schizonticidal activity against P. berghei. Rapid induction of parasite resistance, however, stalled its further development. We have completed a full structure-activity relationship study on 4(1H)-quinolones, focusing on the reduction of cross-resistance with atovaquone for activity against the clinical isolates W2 and TM90-C2B, as well as the improvement of microsomal stability. These studies revealed several frontrunner compounds with superb in vivo antimalarial activity. The best compounds were found to be curative with all mice surviving a Plasmodium berghei infection after 30 days.
机译:尽管自2000年以来全球疟疾死亡率下降了48%,但据报道,对当前疗法的抗药性可能逆转这一进展。近来,曾经被认为不适合用作治疗剂的抗疟药已被重新研究,以提高选择药物候选物所需的理化性质和功效。一种这样的化合物是4(1H)-喹诺酮ICI 56,780,已知其为因果预防剂,其还显示出针对伯氏疟原虫的血生裂殖体活性。然而,寄生虫抗性的快速诱导阻碍了其进一步的发展。我们已经完成了对4(1H)-喹诺酮类化合物的完整的结构-活性关系研究,重点是减少与阿托瓦醌的交叉耐药性对临床分离株W2和TM90-C2B的活性,以及​​提高微粒体的稳定性。这些研究揭示了几种具有卓越的体内抗疟疾活性的先锋化合物。发现最好的化合物对所有在30天后感染了伯氏疟原虫的小鼠均具有治愈作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号